Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Ramos

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Science Advances|August 7, 2024
Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zoneEmily S Norton, Lauren A Whaley, Vanessa K Jones, et al.
Journal of Neuro-Oncology|June 14, 2022
The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter studyAndres Ramos-Fresnedo, Ricardo A Domingo, Carlos Perez-Vega, et al.
Journal of Neurosurgery|November 19, 2021
The impact of multiple lesions on progression-free survival of meningiomas: a 10-year multicenter experienceAndres Ramos-Fresnedo, Ricardo A Domingo, Jesus E Sanchez-Garavito, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Cell-specific crosstalk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zoneEmily S Norton, Lauren A Whaley, Vanessa K Jones, et al.
Neurosurgery Practice|February 17, 2025
Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial ProtocolAndres Ramos-Fresnedo, Rawan Al-Kharboosh, Erin L Twohy, et al.
Neurosurgery Practice|March 11, 2024
Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial ProtocolAndres Ramos-Fresnedo, Rawan Al-Kharboosh, Erin L Twohy, et al.
Journal of Neurosurgery|October 29, 2021
IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical modelShashwat Tripathi, Tito Vivas-Buitrago, Ricardo A Domingo, et al.
Journal of Neuro-Oncology|February 17, 2022
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter studyAndres Ramos-Fresnedo, Michael W Pullen, Carlos Perez-Vega, et al.
Nature Structural & Molecular Biology|September 8, 2012
In support of the BMRBJohn L Markley, Hideo Akutsu, Tetsuo Asakura, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Science Advances|August 7, 2024
Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zoneEmily S Norton, Lauren A Whaley, Vanessa K Jones, et al.
Journal of Neuro-Oncology|June 14, 2022
The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter studyAndres Ramos-Fresnedo, Ricardo A Domingo, Carlos Perez-Vega, et al.
Journal of Neurosurgery|November 19, 2021
The impact of multiple lesions on progression-free survival of meningiomas: a 10-year multicenter experienceAndres Ramos-Fresnedo, Ricardo A Domingo, Jesus E Sanchez-Garavito, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Cell-specific crosstalk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zoneEmily S Norton, Lauren A Whaley, Vanessa K Jones, et al.
Neurosurgery Practice|February 17, 2025
Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial ProtocolAndres Ramos-Fresnedo, Rawan Al-Kharboosh, Erin L Twohy, et al.
Neurosurgery Practice|March 11, 2024
Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial ProtocolAndres Ramos-Fresnedo, Rawan Al-Kharboosh, Erin L Twohy, et al.
Journal of Neurosurgery|October 29, 2021
IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical modelShashwat Tripathi, Tito Vivas-Buitrago, Ricardo A Domingo, et al.
Journal of Neuro-Oncology|February 17, 2022
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter studyAndres Ramos-Fresnedo, Michael W Pullen, Carlos Perez-Vega, et al.
Nature Structural & Molecular Biology|September 8, 2012
In support of the BMRBJohn L Markley, Hideo Akutsu, Tetsuo Asakura, et al.
Pageof 11